1. Home
  2. SSRM vs IMVT Comparison

SSRM vs IMVT Comparison

Compare SSRM & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SSR Mining Inc.

SSRM

SSR Mining Inc.

N/A

Current Price

$29.52

Market Cap

6.5B

Sector

Industrials

ML Signal

N/A

Logo Immunovant Inc.

IMVT

Immunovant Inc.

N/A

Current Price

$25.93

Market Cap

5.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SSRM
IMVT
Founded
1946
2018
Country
United States
United States
Employees
2900
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
5.4B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SSRM
IMVT
Price
$29.52
$25.93
Analyst Decision
Hold
Buy
Analyst Count
4
9
Target Price
$26.74
$30.78
AVG Volume (30 Days)
4.3M
1.1M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$58.93
N/A
Revenue Next Year
$6.60
N/A
P/E Ratio
$14.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.65
$12.72
52 Week High
$33.49
$29.25

Technical Indicators

Market Signals
Indicator
SSRM
IMVT
Relative Strength Index (RSI) 53.72 47.13
Support Level $21.57 $24.63
Resistance Level N/A $27.71
Average True Range (ATR) 1.94 1.10
MACD -0.13 -0.10
Stochastic Oscillator 55.92 29.22

Price Performance

Historical Comparison
SSRM
IMVT

About SSRM SSR Mining Inc.

SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: